Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The present study (CL3‐95008‐002) was performed in children from 2 to less than 7 years old presenting with ASD. A 6‐month double‐blind treatment period was performed in which efficacy and safety of bumetanide 0.5mg BID were assessed versus placebo. This double‐blind period was followed by a 6‐month open label treatment period of bumetanide 0.5mg twice daily in which long term safety was evaluated.
Epistemonikos ID: 73f71edad71d5c75908fd430556037400f45fcd1
First added on: May 21, 2024